BlackRock Inc. Takes Position in Glaukos Corporation $GKOS

BlackRock Inc. acquired a new position in shares of Glaukos Corporation (NYSE:GKOS - Free Report) during the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund acquired 9,540,056 shares of the medical instruments supplier's stock, valued at approximately $1,333,318,000. BlackRock Inc. owned about 16.17% of Glaukos at the end of the most recent reporting period.

A number of other large investors have also recently made changes to their positions in the company. First Horizon Corp grew its holdings in shares of Glaukos by 1,715.4% in the fourth quarter. First Horizon Corp now owns 236 shares of the medical instruments supplier's stock worth $27,000 after purchasing an additional 223 shares during the last quarter. Los Angeles Capital Management LLC purchased a new stake in shares of Glaukos in the fourth quarter valued at approximately $28,000. Larson Financial Group LLC grew its stake in Glaukos by 62.0% in the fourth quarter. Larson Financial Group LLC now owns 345 shares of the medical instruments supplier's stock worth $39,000 after purchasing an additional 132 shares in the last quarter. Parallel Advisors LLC increased its holdings in Glaukos by 159.2% during the 1st quarter. Parallel Advisors LLC now owns 368 shares of the medical instruments supplier's stock worth $40,000 after purchasing an additional 226 shares during the period. Finally, Farther Finance Advisors LLC raised its position in Glaukos by 111.4% during the 4th quarter. Farther Finance Advisors LLC now owns 408 shares of the medical instruments supplier's stock valued at $46,000 after purchasing an additional 215 shares in the last quarter. 99.04% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

GKOS has been the topic of several research reports. Truist Financial raised their price target on Glaukos from $180.00 to $215.00 and gave the company a "buy" rating in a research note on Thursday, July 30th. Needham & Company LLC raised their target price on shares of Glaukos from $150.00 to $201.00 and gave the company a "buy" rating in a research report on Thursday, July 30th. William Blair restated an "outperform" rating on shares of Glaukos in a report on Tuesday, May 26th. Stifel Nicolaus increased their price objective on shares of Glaukos from $175.00 to $190.00 and gave the company a "buy" rating in a research note on Thursday, July 30th. Finally, Wall Street Zen raised shares of Glaukos from a "hold" rating to a "buy" rating in a report on Saturday, August 1st. Twelve equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, Glaukos presently has an average rating of "Moderate Buy" and a consensus target price of $178.08.

Insider Activity at Glaukos

In other news, Director Gilbert H. Kliman sold 2,500 shares of the company's stock in a transaction dated Wednesday, August 19th. The stock was sold at an average price of $190.00, for a total value of $475,000.00. Following the sale, the director owned 37,406 shares in the company, valued at $7,107,140. This represents a 6.26% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, COO Joseph E. Gilliam sold 60,000 shares of Glaukos stock in a transaction that occurred on Tuesday, August 11th. The shares were sold at an average price of $179.74, for a total value of $10,784,400.00. Following the transaction, the chief operating officer owned 72,588 shares of the company's stock, valued at approximately $13,046,967.12. This represents a 45.25% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold 113,025 shares of company stock valued at $19,600,006 over the last three months. 5.90% of the stock is owned by corporate insiders.

Glaukos Price Performance

Shares of GKOS opened at $185.25 on Friday. The company has a 50 day moving average of $156.20 and a two-hundred day moving average of $131.24. The company has a quick ratio of 4.46, a current ratio of 5.04 and a debt-to-equity ratio of 0.10. Glaukos Corporation has a twelve month low of $73.16 and a twelve month high of $191.62. The company has a market cap of $10.93 billion, a price-to-earnings ratio of -57.00 and a beta of 0.78.

Glaukos (NYSE:GKOS - Get Free Report) last announced its earnings results on Wednesday, July 29th. The medical instruments supplier reported ($0.14) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.21) by $0.07. The company had revenue of $185.61 million for the quarter, compared to analyst estimates of $150.93 million. Glaukos had a negative return on equity of 6.37% and a negative net margin of 30.68%.The firm's quarterly revenue was up 49.6% compared to the same quarter last year. During the same period in the prior year, the company posted ($0.24) EPS. As a group, analysts predict that Glaukos Corporation will post -0.35 earnings per share for the current fiscal year.

More Glaukos News

Here are the key news stories impacting Glaukos this week:

• Positive Sentiment: Higher analyst price target: BTIG Research raised its target for Glaukos from $193 to $202 and reiterated a “Buy” rating, citing additional potential upside for the shares. Benzinga
• Positive Sentiment: Strong product momentum: Glaukos’ iDose TR glaucoma implant and Epioxa corneal treatment launch are driving record growth, supporting higher 2026 guidance and expanding the company’s ophthalmology platform. The catalysts have helped the stock gain roughly 67% year to date. GKOS Stock Surges 67% Year to Date: What’s Driving the Rally?
• Positive Sentiment: Improving earnings outlook: Zacks Research raised its FY2027 EPS forecast to $0.45 from $0.38 and its FY2028 estimate to $1.70 from $1.56. It also increased several quarterly estimates, signaling expectations for accelerating profitability as newer products gain adoption.
• Neutral Sentiment: Investor-relations event: Management will participate in the Wells Fargo Healthcare Conference on September 9, which could provide updates on iDose TR, Epioxa, guidance and the development pipeline. Glaukos Announces Participation in Wells Fargo Healthcare Conference
• Negative Sentiment: Near-term profitability remains limited: Glaukos is still expected to post a loss for the current fiscal year, and Zacks modestly reduced its Q2 2027 EPS estimate to $0.06 from $0.07. After the sharp rally, these factors may encourage investors to lock in gains and question the stock’s valuation.

Glaukos Profile

Glaukos Corporation is a medical technology company specializing in the development, manufacturing and commercialization of innovative therapies for patients with glaucoma and other chronic eye diseases. The company's core offerings focus on micro-invasive glaucoma surgery (MIGS), designed to reduce intraocular pressure and manage glaucoma more safely and effectively than traditional surgical approaches. Glaukos's flagship products include the iStent, iStent inject and iStent infinite trabecular micro-bypass stents, which are implanted during cataract surgery to improve aqueous outflow and help control eye pressure.

Beyond its MIGS portfolio, Glaukos has expanded into sustained drug-delivery solutions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source